Inpatient Cell Therapy, Outpatient BMT Clinic
PharmD: Belmont University
PGY1: University of Chicago Medicine
PGY2 Oncology: University of Chicago Medicine
Cellular therapy, immunocompromised ID
Hematology/Oncology Pharmacists Association (HOPA)
American Society for Transplantation and Cellular Therapy (ASTCT) - Research SIG Committee Member
Advanced Topics for Oncology Pharmacy Professionals (ATOPP) - Planning Committee
Collins J, Serbas L, Parsad S. Considerations for Initiation of Lu-Dotatate therapy at a large academic medical center. Oncolytics Today. 2021. 35-39. https://www.ncoda.org/oncolytics-today/current-issue/#1
Riedell PA, Wu Meng, Collins JM, et al. Bloodless chimeric antigenreceptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk & Lymphoma. 2020. https://doi.org/10.1080/10428194.2021.1876868.
Major A, Collins JM, Craney C, et al. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: A case report and review of the literature. Leuk & Lymphoma. 2020. https://doi.org/10.1080/10428194.2021.1881507.
Collins JM, Gawedzki P. Impact of the Implementation of a Pharmacist-Driven Immunosuppression Drug Monitoring Protocol for Hematopoietic Stem Cell Transplant Recipients Biology of Blood and Marrow Transplantation. J Oncol Pharm Practice. 2020. 1-7. https://doi.org/10.1177/1078155220975088
Collins JM, Dennis EE, Green MW, and Greene EM. Patient self-prescription and antimicrobial stewardship: considerations for primary care. J APhA. 2020. 1-4. https://doi.org/10.1016/j.japh.2020.03.012.
Collins JM, et al. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. J Oncol Pharm Practice. 2019. DOI 10.1177/1078155219833440
Collins JM, Flemin GF, and Christ TN. Comparison of the incidence of febrile neutropenia in obese and and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Practice. 2018. DOI 10.1177/1078155218776471
Collins JM, Duvall AS, Dworkin E, Stock W, and Castiel M. A systematic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients. Pending.
Academic and/or National Presentations
Immune Effector Cell Therapy Part I: Basics and Updates. 2022 ASTCT Fundamentals of HCT Training Course (Virtual)
Best Practices: CAR-T Therapy Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR February 2022? (Salt Lake City, UT)
Effect of Posaconazole on Tacrolimus Levels in Allogeneic Stem Cell Transplant Patients - May 2018 at the HOPA Annual Conference (Denver, CO)
QTc Monitoring in Patients on Prophylactic Azithromycin and Antidepressants - December 2017 at the ASHP Midyear Meeting (Orlando, FL)
Incidence of Febrile Neutropenia in Obese Breast Cancer Patients Receiving Pegfilgrastim - December 2016 at the ASHP Midyear Meeting (Las Vegas, NV)
Antimicrobial Stewardship: Considerations for Primary Care - December 2015 at the ASHP Midyear Meeting (New Orleans, LA)
Impact of Neutrophil-Mediated Initiation of Anti-Infective Prophylaxis in Cell Therapy Patients
The Influence of Gut Decontamination Prophylactic Antibiotics on Allogeneic Hematopoietic Stem Cell Transplant Outcomes In Collaboration with Kaitlin Kelly, PharmD
Association of Tacrolimus Levels with GVHD Incidence and Toxicity In Collaboration with Mylove Mortel, MSPH, RN, OCN and Zaheera Shabbir, PharmD
The Utility of Proton Pump Inhibitor Prophylaxis in Hematologic Cancer Patients in Collaboration with Ben Bowar, PharmD